In patients with metastatic NSCLC with EGFR mutation currently being treated with osimertinib, would you consider increasing dose from 80mg to 160mg at the time of progression?  

For systemic progression would not increase dose. If PD only brain mets and asymptomatic would consider raising dose and continuing.  If brain mets only were symptomatic would do SBRT and consider increasing dose.